BioCentury
ARTICLE | Company News

Sanquin Blood Supply, Synthon deal

March 10, 2017 7:56 PM UTC

Sanquin granted Synthon exclusive, worldwide rights to develop immuno-oncology therapeutics using Sanquin’s antibodies that modulate CD47-signal regulatory protein alpha (SIRPA; CD172a, SHPS-1) intera...

BCIQ Company Profiles

Synthon B.V.